Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus

Alan J. Guthrie, Melvyn Quan, Carina W. Lourens, Jean Christophe Audonnet, Jules M. Minke, Jiansheng Yao, Ling He, Robert Nordgren, Ian Gardner, Nigel J Maclachlan

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We describe the development and preliminary characterization of a recombinant canarypox virus vectored (ALVAC®) vaccine for protective immunization of equids against African horse sickness virus (AHSV) infection. Horses (n = 8) immunized with either of two concentrations of recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) developed variable titres (<10-80) of virus-specific neutralizing antibodies and were completely resistant to challenge infection with a virulent strain of AHSV-4. In contrast, a horse immunized with a commercial recombinant canarypox virus vectored vaccine expressing the haemagglutinin genes of two equine influenza H3N8 viruses was seronegative to AHSV and following infection with virulent AHSV-4 developed pyrexia, thrombocytopenia and marked oedema of the supraorbital fossae typical of the "dikkop" or cardiac form of African horse sickness. AHSV was detected by virus isolation and quantitative reverse transcriptase polymerase chain reaction in the blood of the control horse from 8 days onwards after challenge infection whereas AHSV was not detected at any time in the blood of the ALVAC-AHSV vaccinated horses. The control horse seroconverted to AHSV by 2 weeks after challenge infection as determined by both virus neutralization and ELISA assays, whereas six of eight of the ALVAC-AHSV vaccinated horses did not seroconvert by either assay following challenge infection with virulent AHSV-4. These data confirm that the ALVAC-AHSV vaccine will be useful for the protective immunization of equids against African horse sickness, and avoids many of the problems inherent to live-attenuated AHSV vaccines.

Original languageEnglish (US)
Pages (from-to)4434-4438
Number of pages5
JournalVaccine
Volume27
Issue number33
DOIs
StatePublished - Jul 16 2009

Fingerprint

Canarypox virus
African Horse Sickness Virus
African horse sickness virus
Capsid Proteins
coat proteins
Horses
Immunization
immunization
Vaccines
vaccines
horses
Genes
genes
African Horse Sickness
African horse sickness
infection
Virus Diseases
Viruses
Infection
H3N8 Subtype Influenza A Virus

Keywords

  • African horse sickness
  • Canarypox virus
  • Horses
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. / Guthrie, Alan J.; Quan, Melvyn; Lourens, Carina W.; Audonnet, Jean Christophe; Minke, Jules M.; Yao, Jiansheng; He, Ling; Nordgren, Robert; Gardner, Ian; Maclachlan, Nigel J.

In: Vaccine, Vol. 27, No. 33, 16.07.2009, p. 4434-4438.

Research output: Contribution to journalArticle

Guthrie, Alan J. ; Quan, Melvyn ; Lourens, Carina W. ; Audonnet, Jean Christophe ; Minke, Jules M. ; Yao, Jiansheng ; He, Ling ; Nordgren, Robert ; Gardner, Ian ; Maclachlan, Nigel J. / Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. In: Vaccine. 2009 ; Vol. 27, No. 33. pp. 4434-4438.
@article{6e33c171d86649eca9720e465d01abc9,
title = "Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus",
abstract = "We describe the development and preliminary characterization of a recombinant canarypox virus vectored (ALVAC{\circledR}) vaccine for protective immunization of equids against African horse sickness virus (AHSV) infection. Horses (n = 8) immunized with either of two concentrations of recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) developed variable titres (<10-80) of virus-specific neutralizing antibodies and were completely resistant to challenge infection with a virulent strain of AHSV-4. In contrast, a horse immunized with a commercial recombinant canarypox virus vectored vaccine expressing the haemagglutinin genes of two equine influenza H3N8 viruses was seronegative to AHSV and following infection with virulent AHSV-4 developed pyrexia, thrombocytopenia and marked oedema of the supraorbital fossae typical of the {"}dikkop{"} or cardiac form of African horse sickness. AHSV was detected by virus isolation and quantitative reverse transcriptase polymerase chain reaction in the blood of the control horse from 8 days onwards after challenge infection whereas AHSV was not detected at any time in the blood of the ALVAC-AHSV vaccinated horses. The control horse seroconverted to AHSV by 2 weeks after challenge infection as determined by both virus neutralization and ELISA assays, whereas six of eight of the ALVAC-AHSV vaccinated horses did not seroconvert by either assay following challenge infection with virulent AHSV-4. These data confirm that the ALVAC-AHSV vaccine will be useful for the protective immunization of equids against African horse sickness, and avoids many of the problems inherent to live-attenuated AHSV vaccines.",
keywords = "African horse sickness, Canarypox virus, Horses, Vaccine",
author = "Guthrie, {Alan J.} and Melvyn Quan and Lourens, {Carina W.} and Audonnet, {Jean Christophe} and Minke, {Jules M.} and Jiansheng Yao and Ling He and Robert Nordgren and Ian Gardner and Maclachlan, {Nigel J}",
year = "2009",
month = "7",
day = "16",
doi = "10.1016/j.vaccine.2009.05.044",
language = "English (US)",
volume = "27",
pages = "4434--4438",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "33",

}

TY - JOUR

T1 - Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus

AU - Guthrie, Alan J.

AU - Quan, Melvyn

AU - Lourens, Carina W.

AU - Audonnet, Jean Christophe

AU - Minke, Jules M.

AU - Yao, Jiansheng

AU - He, Ling

AU - Nordgren, Robert

AU - Gardner, Ian

AU - Maclachlan, Nigel J

PY - 2009/7/16

Y1 - 2009/7/16

N2 - We describe the development and preliminary characterization of a recombinant canarypox virus vectored (ALVAC®) vaccine for protective immunization of equids against African horse sickness virus (AHSV) infection. Horses (n = 8) immunized with either of two concentrations of recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) developed variable titres (<10-80) of virus-specific neutralizing antibodies and were completely resistant to challenge infection with a virulent strain of AHSV-4. In contrast, a horse immunized with a commercial recombinant canarypox virus vectored vaccine expressing the haemagglutinin genes of two equine influenza H3N8 viruses was seronegative to AHSV and following infection with virulent AHSV-4 developed pyrexia, thrombocytopenia and marked oedema of the supraorbital fossae typical of the "dikkop" or cardiac form of African horse sickness. AHSV was detected by virus isolation and quantitative reverse transcriptase polymerase chain reaction in the blood of the control horse from 8 days onwards after challenge infection whereas AHSV was not detected at any time in the blood of the ALVAC-AHSV vaccinated horses. The control horse seroconverted to AHSV by 2 weeks after challenge infection as determined by both virus neutralization and ELISA assays, whereas six of eight of the ALVAC-AHSV vaccinated horses did not seroconvert by either assay following challenge infection with virulent AHSV-4. These data confirm that the ALVAC-AHSV vaccine will be useful for the protective immunization of equids against African horse sickness, and avoids many of the problems inherent to live-attenuated AHSV vaccines.

AB - We describe the development and preliminary characterization of a recombinant canarypox virus vectored (ALVAC®) vaccine for protective immunization of equids against African horse sickness virus (AHSV) infection. Horses (n = 8) immunized with either of two concentrations of recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) developed variable titres (<10-80) of virus-specific neutralizing antibodies and were completely resistant to challenge infection with a virulent strain of AHSV-4. In contrast, a horse immunized with a commercial recombinant canarypox virus vectored vaccine expressing the haemagglutinin genes of two equine influenza H3N8 viruses was seronegative to AHSV and following infection with virulent AHSV-4 developed pyrexia, thrombocytopenia and marked oedema of the supraorbital fossae typical of the "dikkop" or cardiac form of African horse sickness. AHSV was detected by virus isolation and quantitative reverse transcriptase polymerase chain reaction in the blood of the control horse from 8 days onwards after challenge infection whereas AHSV was not detected at any time in the blood of the ALVAC-AHSV vaccinated horses. The control horse seroconverted to AHSV by 2 weeks after challenge infection as determined by both virus neutralization and ELISA assays, whereas six of eight of the ALVAC-AHSV vaccinated horses did not seroconvert by either assay following challenge infection with virulent AHSV-4. These data confirm that the ALVAC-AHSV vaccine will be useful for the protective immunization of equids against African horse sickness, and avoids many of the problems inherent to live-attenuated AHSV vaccines.

KW - African horse sickness

KW - Canarypox virus

KW - Horses

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=67649306196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649306196&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.05.044

DO - 10.1016/j.vaccine.2009.05.044

M3 - Article

C2 - 19490959

AN - SCOPUS:67649306196

VL - 27

SP - 4434

EP - 4438

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 33

ER -